These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36652353)

  • 1. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
    Winokur P; Gayed J; Fitz-Patrick D; Thomas SJ; Diya O; Lockhart S; Xu X; Zhang Y; Bangad V; Schwartz HI; Denham D; Cardona JF; Usdan L; Ginis J; Mensa FJ; Zou J; Xie X; Shi PY; Lu C; Buitrago S; Scully IL; Cooper D; Koury K; Jansen KU; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    N Engl J Med; 2023 Jan; 388(3):214-227. PubMed ID: 36652353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
    Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
    Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
    Barda N; Lustig Y; Indenbaum V; Zibly D; Joseph G; Asraf K; Weiss-Ottolenghi Y; Amit S; Kliker L; Abd Elkader B; Ben-Ami E; Canetti M; Koren R; Katz-Likvornik S; Halpern O; Mendelson E; Doolman R; Harats D; Kreiss Y; Mandelboim M; Regev-Yochay G
    Clin Microbiol Infect; 2023 Jul; 29(7):918-923. PubMed ID: 36921715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
    Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.
    Sher LD; Boakye-Appiah JK; Hill S; Wasserman E; Xu X; Maldonado Y; Walter EB; Muñoz FM; Paulsen GC; Englund JA; Talaat KR; Barnett ED; Kamidani S; Senders S; Simões EAF; Belanger K; Parikh V; Ma H; Wang X; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Gurtman A; Kitchin N; Sabharwal C
    J Pediatric Infect Dis Soc; 2024 Aug; 13(8):421-429. PubMed ID: 38860591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Chalkias S; Whatley JL; Eder F; Essink B; Khetan S; Bradley P; Brosz A; McGhee N; Tomassini JE; Chen X; Zhao X; Sutherland A; Shen X; Girard B; Edwards DK; Feng J; Zhou H; Walsh S; Montefiori DC; Baden LR; Miller JM; Das R
    Nat Med; 2023 Sep; 29(9):2325-2333. PubMed ID: 37653342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
    Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
    Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
    Gayed J; Diya O; Lowry FS; Xu X; Bangad V; Mensa F; Zou J; Xie X; Hu Y; Lu C; Cutler M; Belanger T; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Modjarrad K; Gurtman A; Kitchin N;
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
    Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
    Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.